



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Bondarev

Serial No.: 10/758,329

Filing Date: January 15, 2004

Attorney Docket No.: 04-40018-US

Group Art Unit: 1635

TITLE: MODULATION OF LINE-1
REVERSE TRANSCRIPTASE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)(4)

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The above-identified Applicant submits herewith references, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. Form PTO-1449, attached hereto, lists the references of which Applicant is aware, and which may be material to the examination of this application.

While the information cited in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. § 1.56, the filing of these references should not be construed to be an admission that any patent, publication or other information referred to herein is, or is considered to be, either "prior art" for this invention or otherwise material to the patentability of this invention as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(4) ("before the mailing of a first Office Action after the filing of a request for continued examination") and therefore it is believed no fee is due. The Commissioner is hereby authorized to charge any additional fees and credit overpayment to Deposit Account No. 18-0586.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label Number: EV 700640691 US
Date of Deposit: June 13, 2007

I hereby certify that this paper and/or fee is being deposited with the United States Postal Service, "EXPRESS MAIL - POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and is addressed to MAIL STOP RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

Lorraine Zandona
(Name of person mailing paper.)

(Signature of person mailing paper.)

Respectfully submitted,



Nanda P.B.A. Kumar
Registration No. 44,853
REED SMITH LLP
2500 One Liberty Place
1650 Market Street
Philadelphia, PA 19101
(215) 241-7991

Attorney for Applicant

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
04-40018-US

SER. NO.
10/758,329



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

Bondarev

FILING DATE

January 15, 2004

GROUP

1635

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AA	5,707,795	01/13/1998	West et al.		
	AB	6,004,939	12/21/1999	Chen et al.		

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BA					

OTHER DOCUMENTS
(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	Document Description
	CA	Gellert et al., "Telomerase as a Therapeutic Target in Cancer," Drug Discovery Today: Disease Mechanisms, Vol. 2, No. 2, 2005, pp. 159-164.
	CB	Herbert et al., "Telomerase and Breast Cancer," Breast Cancer Res, Vol. 3, No. 3, 2001, pp. 146-149.
	CC	Melana et al., "Inhibition of Cell Growth and Telomerase Activity of Breast Cancer Cells <i>in Vitro</i> by 3' -Azido-3' -deoxythymidine ¹ ," Clinical Cancer Research, Vol. 4, March 1998, pp. 693-696.
EXAMINER		DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.